Drug intelligence / Profile preview

acyline

Development stage: Phase 2
Lead developer: Merrion Pharmaceuticals
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Oral

Overview

Acyline is a synthetic decapeptide that acts as a potent gonadotropin-releasing hormone (GnRH) antagonist. It suppresses the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone levels in men. Acyline was developed for potential use in conditions such as hypogonadism, prostate cancer, and male contraception. It is not orally active under normal circumstances and has been administered by subcutaneous injection; oral formulations were also investigated using specialized delivery technology. Clinical development reached Phase II but was discontinued before marketing[1][2][3][4][5][6].

Other names: acylineMER-104MER104MER 104

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on acyline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acyline.

Explore the full profile